The efficacy of low dose short-term prednisone therapy for remission induction in newly diagnosed rheumatoid arthritis patients
Open Access
- 9 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Advances in Rheumatology
- Vol. 61 (1), 1-6
- https://doi.org/10.1186/s42358-021-00205-4
Abstract
The ACR/EULAR recommendations endorse the use of glucocorticoids (GCs) for rheumatoid arthritis (RA) patients’ flares and as a bridge to a DMARD. However, the recommendation of low dose short-term monotherapy with (GCs) remains open to the discretion of the clinician. The aim of this study was to assess whether a short-term use of low dose prednisone monotherapy was effective in inducing remission in newly diagnosed RA patients. A retrospective analysis of patients newly diagnosed with RA at a Community Health Center in North Dakota was performed based on the ACR/EULAR RA classification criteria. Demographic and clinical data were abstracted from patients’ medical charts. Patients treated with (< 10 mg/day) of prednisone up to 6 months were included. Response to prednisone was analyzed according to pre- and post-treatment DAS28-ESR score and EULAR response criteria. Data on 201 patients were analyzed. The mean prednisone dose was 8 mg/day (range: 5–10; SD = 1.2) and the mean treatment duration was 42.2 days (12–177; 16.9). Disease severity significantly improved from baseline to follow-up for: tender joint count (8.6 ± 4.8 vs. 1.5 ± 3.3; P < 0.001), swollen joint count (6.2 ± 5.0 vs. 1.4 ± 3.0; P < 0.001), and visual analog pain score (4.8 ± 2.6 vs. 2.1 ± 2.5; P < 0.001). DAS28-ESR disease severity significantly improved from baseline to follow-up: (5.1 ± 1.2 vs. 2.7 ± 1.3; P < 0.001). Per EULAR response criteria, 69.7% of patients showed good response to treatment and 20.4% showed moderate response. 54.2% of patients reached remission. Short-term use of low dose prednisone monotherapy induced disease remission and improved clinical severity of RA in the majority of newly diagnosed patients.Keywords
This publication has 33 references indexed in Scilit:
- Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis. Results of a 12 month open-label randomized study.Arthritis Research & Therapy, 2012
- Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practiceAnnals Of The Rheumatic Diseases, 2010
- Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysisRheumatology, 2009
- Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2009
- Disease status, costs and quality of life of patients with rheumatoid arthritis in France: The ECO-PR StudyJoint Bone Spine, 2008
- Revisiting the Toxicity of Low‐Dose GlucocorticoidsAnnals of the New York Academy of Sciences, 2006
- Followup radiographic data on patients with rheumatoid arthritis who participated in a two‐year trial of prednisone therapy or placeboArthritis & Rheumatism, 2006
- Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trialArthritis & Rheumatism, 2005
- Short‐term low‐dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritisEmergencias, 2005
- Adrenocortical Hormone in Arthritis : Preliminary ReportAnnals Of The Rheumatic Diseases, 1949